1 资料和方法 1.1 一般资料 所有病例均系我院住院患者,诊断符合1995年全国传染病与寄生虫病学术会议修订的慢性肝炎诊断标准。全部病例不伴有肝硬变,无继发感染,此前未用过RNA和甘利欣,亦未接受过抗病毒和增强免疫治疗,共80例,随机分为治疗组和对照组,两组情况见表1。 1.2 用药方法 治疗组:采用江苏如皋生化制药厂提供的由 1 Materials and Methods 1.1 General Information All cases were hospitalized patients in our hospital, diagnosed in line with the 1995 National Conference on Infectious Diseases and Parasitic Diseases revised chronic hepatitis diagnostic criteria. All cases were not associated with cirrhosis, no secondary infection, no RNA and Glycyrrhizin had been used before, and no antiviral and immunosuppressive therapy. A total of 80 patients were randomly divided into treatment group and control group. See Table 1. 1.2 drug treatment group: Jiangsu Rugao Biochemical Pharmaceutical Factory provided by